Evidence map›Paper›PMID 22302301›Full record

ArticleChest2012

Trends in bronchiectasis among medicare beneficiaries in the United States, 2000 to 2007.

Amy E Seitz, Kenneth N Olivier, Jennifer Adjemian, Steven M Holland, D Rebecca Prevots

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Chest, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02625246 (A Phase I, Trial to Evaluate the Safety, Tolerability, and Potential Efficacy of Allogeneic Human Mesenchymal Stem Cell), which is not on this map. Cited by 138 papers, 19 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
138citing papers in PubMed, 19 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02625246 phase1completednot on this mapstarted 2016, after this paper: background citation

A Phase I, Trial to Evaluate the Safety, Tolerability, and Potential Efficacy of Allogeneic Human Mesenchymal Stem Cell (hMSC) Infusion in Patients With Non-Cystic Fibrosis Bronchiectasis

TypeinterventionalSponsorMarilyn GlassbergRan2016 to 2019Enrolled6ConditionsBronchiectasisArmshMSCs
3 · Its place in the literature

Who cites it

138 citing papers in PubMed, 19 syntheses or guidelines pooled it.

  1. Guideline
  2. Mucolytics for children with chronic suppurative lung disease.The Cochrane database of systematic reviews · 2025
    Pooled it
  3. Pooled it
  4. Exercise training for bronchiectasis.The Cochrane database of systematic reviews · 2021
    Pooled it
  5. Pooled it
  6. Pooled it
  7. Head-to-head trials of antibiotics for bronchiectasis.The Cochrane database of systematic reviews · 2018
    Pooled it
  8. Dual antibiotics for bronchiectasis.The Cochrane database of systematic reviews · 2018
    Pooled it
  9. Oral versus inhaled antibiotics for bronchiectasis.The Cochrane database of systematic reviews · 2018
    Pooled it
  10. Macrolide antibiotics for bronchiectasis.The Cochrane database of systematic reviews · 2018
    Pooled it
  11. Self-management for bronchiectasis.The Cochrane database of systematic reviews · 2018
    Pooled it
  12. Pooled it
  13. Pooled it
  14. Pooled it
  15. Pooled it
  16. Pooled it
  17. Pooled it
  18. Pooled it
  19. Pooled it
  20. Trial

78 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Amy E SeitzEpidemiology Unit, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD; Laboratory of Clinical Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD. Electronic address: seitza@niaid.nih.gov.
Kenneth N OlivierEpidemiology Unit, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD; Laboratory of Clinical Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD.
Jennifer AdjemianEpidemiology Unit, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD; Laboratory of Clinical Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD.
Steven M HollandLaboratory of Clinical Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD.
D Rebecca PrevotsEpidemiology Unit, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD; Laboratory of Clinical Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD.

Funding

Genes And Gene Products As ImmunoadjuvantsZIAAI000647 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI HOLLAND, STEVEN · 2009 to 2025
$22.6M
Epidemiology of Mycobacterial InfectionsZIAAI001035 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI PREVOTS, D. REBECCA · 2009 to 2025
$11.6M
Intramural NIH HHS
6 · The paper itself

Abstract

backgroundBronchiectasis is a potentially serious condition characterized by permanent and abnormal widening of the airways, the prevalence of which is not well described. We sought to describe the trends, associated conditions, and risk factors for bronchiectasis among adults aged ≥ 65 years.

methodsA 5% sample of the Medicare outpatient claims database was analyzed for bronchiectasis trends among beneficiaries aged ≥ 65 years from 2000 to 2007. Bronchiectasis was identified using International Classification of Diseases, Ninth Revision, Clinical Modification claim diagnosis codes for acquired bronchiectasis. Period prevalence was used to describe sex- and race/ethnicity-specific rates, and annual prevalence was used to describe trends and age-specific rates. We estimated trends using Poisson regression and odds of bronchiectasis using multivariate logistic regression.

resultsFrom 2000 to 2007, 22,296 people had at least one claim for bronchiectasis. The 8-year period prevalence of bronchiectasis was 1,106 cases per 100,000 people. Bronchiectasis increased by 8.7% per year. We identified an interaction between the number of thoracic CT scans and race/ethnicity; period prevalence varied by a greater degree by number of thoracic CT scans among Asians compared with whites or blacks. Among people with one CT scan, Asians had a 2.5- and 3.9-fold higher period prevalence compared with whites and blacks.

conclusionsBronchiectasis prevalence increased significantly from 2000 to 2007 in the Medicare outpatient setting and varied by age, sex, and race/ethnicity. This increase could be due to a true increase in the condition or an increased recognition of previously undiagnosed cases.

Indexed as

MedicareAgedAged, 80 and overAge DistributionBronchiectasisEthnicityFemaleHumansMalePrevalenceRisk FactorsSex DistributionUnited StatesWhite People

Identifiers

PMID22302301
PMCPMC3425339

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.